Pharmacovigilance Market Opportunities and Growth Forecast To 2020

Pharmacovigilance Market: Overview

The increasing occurrence of adverse drug reaction (ADR) and the rising policies implemented by governments on drug safety regulations globally will fuel the growth of the global pharmacovigilance market. The market for pharmacovigilance has been growing in leaps and bounds owing to the increasing aging population, raising the introduction of new drugs. Furthermore, health regulatory authorities including EMEA and the U.S. FDA are pressurizing on submission of data through electronic mediums. This will also positively impact the growth of the global pharmacovigilance market.

Get Sample Research Report @: http://bit.ly/2lUVxz5

This report presents quantitative information sets and elaborates upon the market dynamics such as the future prospects, drivers, and challenges. The competitive analysis tools such as attractive investment proposition have also been employed in order to present an accurate understanding of the overall market. The top regional segment driving the growth of the global pharmacovigilance market also forms a key part of this study.

In the competitive landscape section of the report, the main sustainability strategies implemented by the leading players and their impact on the development of the market have also been presented. The key market regulating factors have also been detailed under this study. Key monitoring tools such as SWOT analysis and Porter’s five forces analysis have also been utilized in order to provide a detailed understanding of the competition present in the overall pharmacovigilance market.

Pharmacovigilance Market: Drivers and Restraints

The increasing awareness amongst individuals on the safe utilization of medical interventions and medicines is amongst the key factors providing impetus to the development of the pharmacovigilance market. In addition, the rising count of national pharmacovigilance centers worldwide is positively impacting the growth of the overall market for pharmacovigilance. These centers are increasing awareness regarding safety of drugs amongst individuals, hence catapulting demand for pharmacovigilance.

On the other hand, the huge risk of data security and increasing perception on benefits or harmful effects of various drugs are amongst the key factors restraining the development of the market. In addition, the trend of web-based sales and drug information and the lack of skilled professionals may negatively impact the growth of the global pharmacovigilance market.

Pharmacovigilance Market: Region-wise Outlook

On the basis of geography, the global pharmacovigilance market is segmented into Europe, North America, Asia Pacific, and Rest of the World (RoW). Of these, the North America pharmacovigilance market held a significant share in the past owing to the rising mortality rate in this region because of increasing occurrence rate of ADRS and the growing concern on patients about the efficacy and safety of pharmaceutical products.

However, Asia Pacific is predicted to emerge as the most lucrative region in the market in the coming years. This is due to the rising demand for strict regulations on healthcare in Asia Pacific and the large pool of patients within this region. In addition, the growing need for effective pharmacovigilance services owing to the increasing count of clinical trials taking place in a number of Asia Pacific nations will also boost the development of the overall market.

Browse Full Report @: http://www.transparencymarketresearch.com/pharmacovigilance-market.html

Key players Mentioned in the Report are:

The top players in this market are Clinquest Group B.V., Accenture, Plc, Cognizant Technology Solutions, iMED Global Corporation, Covance, Inc. ICON, Plc, inVentiv Health, Inc., Pharmaceutical Product Development LLC, Parexel International Corporation, PRA Health Sciences, Inc., F. Hoffmann-La Roche Ltd., Quintiles Transnational Holdings Inc, Sanofi , Wipro Limited, and Synowledge LLC, among others.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Retinal Surgery Devices Market Report: Analysis and Forecast 2020

Retinal surgery devices are undergoing rapid technological advancement to establish an effective treatment platform for various retinal diseases. For instance, minimally invasive surgical instruments for the treatment of retinal diseases offer advantages such as lesser pain, minor scarring, quick recovery and reduced health care costs. Applications of retinal surgery devices across various ophthalmic conditions such as diabetic retinopathy, retinal detachment, epiretinal membrane and macular hole are driving the growth of the global retinal surgery devices market. Furthermore, increasing geriatric population is fueling the growth of the market, as these individuals are reported to be at a higher risk of developing eye-related disorders.

Get Sample Research Report @: http://bit.ly/2mruf6N

In terms of type of equipment, the retinal surgery devices market has been segmented into vitrectomy packs, vitrectomy machines, retinal laser equipment, microscopic illumination equipment, surgical instruments and others (retinal tamponades, sclera buckle, etc.) Vitrectomy packs accounted for the largest share of the retinal surgery devices market in terms of revenue in 2013. The segment is expected to grow at the highest CAGR during the forecast period from 2014 to 2020. Factors that contribute to the high growth of vitrectomy packs segment are increased timesaving during and after the retinal surgery procedure by cutting back on the preparation time and the growing demand for single-use sterile packs of surgical instruments in order to cut costs through better inventory management.

Based on applications, the retinal surgery devices market has been segmented into diabetic retinopathy, retinal detachment, epiretinal membrane, macular hole and other applications that include eye infections and eye injuries. The diabetic retinopathy application segment held the largest share of the retinal surgery devices market in 2013 due to high prevalence of diabetic retinopathy across the globe and growing patient preference to opt for retinal surgery as their first treatment option for long-term benefit. However, the retinal detachment application segment is anticipated to grow at the highest CAGR during the forecast period from 2014 to 2020. Factors attributed to the growth of the segment are increasing geriatric population and severe ophthalmic ailments affecting them such as formation of scar tissue on the retina and retinal tear. In addition, retinal surgery offers better results in the treatment of retinal detachment, which boosts the growth of the segment.

Geographically, North America was the largest market for retinal surgery devices in 2013. Factors driving the growth of the retinal surgery devices market in North America are increasing prevalence of eye diseases among the geriatric and diabetic population. According to recent data from the U.S. Centers for Disease Control and Prevention (CDC) in 2014, around 26 million people in the U.S. have diabetes, and over 28% of diabetics aged 40 years and above have diabetic retinopathy and related diabetic eye diseases. Furthermore, technological developments in the field of ophthalmic surgical devices and increasing awareness of the population about surgical treatments of various retinal diseases are boosting the growth of the retinal surgery devices market in North America. However, Asia Pacific is likely to record the highest CAGR during the forecast period. Large population base, greater initiatives taken by the governments to promote health care and robust economic growth are the factors attributed to the high growth in the region. Moreover, improving consumer awareness about eye care and better disease management would drive the growth of the retinal surgery devices market in Asia Pacific.

Browse Full Report @: http://www.transparencymarketresearch.com/retinal-surgery-devices-market.html

The global retinal surgery devices market is fragmented due to the presence of well established as well as emerging companies in this field. The top companies operating in the retinal surgery devices market are Bausch + Lomb Incorporated, Synergetics, Inc., IRIDEX Corporation, Alcon, Inc., Carl Zeiss Meditec AG, Leica Microsystems, NIDEK CO., LTD., Topcon Corporation, Lumenis, and Optos plc.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Albumin Market Segmentation and Analysis Research Report to 2020

Appropriate selection of excipients during the new product development is one of the critical in the pharmaceutical formulations. Criteria for selection of suitable excipient depend on the physical, chemical and biological properties of the excipient. Primarily, it should help stabilize and protect the drug/active pharmaceutical ingredient (API) in the formulation against degradation, oxidation or aggregation, during manufacturing, transport and storage. Preformulation studies comprise investigation of drug-excipient interactions that help in selection of appropriate excipients to achieve the desired properties for the final drug product. Albumin is a well characterized protein and functions as a therapeutic, diagnostic agent, as well as an excipient. As an excipient, albumin has wide applications in drug formulation, drug delivery, vaccine manufacturing and as a component of media in vaccine production. Stable nature of albumin makes its handling and storage easier than other proteins, making it suitable for use as an excipient. Albumin due to its intrinsic stability can be heated at 60°C for 10 hours facilitating virus inactivation during manufacturing.

Get Sample Research Report @: http://bit.ly/2lRFQdW

This report studies the global market for albumin encompassing type, applications and geography. Types of albumin include human serum albumin, bovine serum albumin and recombinant albumin. Major applications for albumin as an excipient comprise drug formulation and drug delivery, vaccines and component of medium. Each of these segments has been analyzed in detail from market trends and recent developments to future outlook and opportunities. The report provides the albumin market size in terms of value (USD million) and volume (kg) for each segment and sub-segment for the period from 2012 to 2020, considering the macro- and micro environmental factors. In addition, the compounded annual growth rate (CAGR) of the overall albumin market and the segments has also been provided in the report for the forecast period 2014 to 2020, considering 2012 as historical year and 2013 as the base year. The global albumin market report also includes an elaborate executive summary, which covers a market snapshot representing key findings from the study.

Geographically, the global albumin market has been segmented into four regions: North America, Europe, Asia Pacific and Rest of the World (RoW). The market size and forecast in terms of value (USD million) and volume (kg) for each of these regions along with the CAGR for the forecast period from 2014 to 2020 have been provided in the report. A detailed qualitative analysis of the major factors determining market dynamics such as drivers, restraints and opportunities, along with the market attractiveness analysis are discussed in the market overview section of the report. The study also provides a list of recommendations for new companies willing to enter the market and for existing companies to increase market shares, which is likely to help in the decision-making process. Event impact analysis and clinical pipeline analysis have also been provided for albumin as an excipient in this report that will help in understanding the major events impacting the albumin market growth. Number of clinical trials also demonstrates the potential of albumin use as an excipient in pharmaceutical formulations.

Browse Full Report @: http://www.transparencymarketresearch.com/albumin-market.html

The study is a robust combination of primary and secondary research. Primary research formed the bulk of our research efforts with information collected from telephonic interviews and interaction via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases for patents, clinical trials, demographics, disease incidence/prevalence, etc. The key players operating in the albumin market are CSL Behring LLC, HiMedia Laboratories Pvt. Ltd., InVitria, MedzBio Pte. Ltd., Mitsubishi Tanabe Pharma Corporation, Novozymes A/S, Octapharma AG, RayBiotech, Inc., Sigma-Aldrich Corporation, and Thermo Fisher Scientific.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Hematological Malignancies Market: Present Scenario and the Growth Prospects 2024

Hematological Malignancies Market: Overview

This report provides in-depth region wise and country wise analysis of the hematological malignancies market. Stakeholders of this report include manufacturers of hematology cancer drugs, raw material suppliers, cancer drug processing companies, and new players planning to enter the market. It further presents qualitative and quantitative analysis of the global hematological malignancies market. Qualitative analysis comprises market dynamics, trends, product overview, and country-level market information.

Request For Sample Report @ http://bit.ly/2l7gXfu

Quantitative analysis includes market share held by companies in 2015, market size, and forecast for the global hematological malignancies market in major countries globally such as the U.S., Canada, Germany, France, United Kingdom, Italy, Spain, Japan, China, Brazil, Mexico, South Africa and Saudi Arabia. Market revenue is provided in terms of US$ Mn from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 for all the segments, considering 2015 as the base year. The executive summary of the report provides a snapshot of the hematological malignancies with information on leading segments, country wise market information with respect to the market size, growth rate (CAGR %), and growth factors.

The market overview section, further, comprises impact factors such as drivers, restraints, and opportunities for the global hematological malignancies market. These factors would aid the stakeholders in establishing a strong foothold in the global hematological malignancies market. Furthermore, the market overview section comprises key industry events, product overview, market attractiveness analysis and emerging trend in the hematological malignancies market. The market attractiveness analysis provides a graphical view comparing the growth and market dynamics in various segments and country wise to identify the most attractive market. Market share analysis is also provided in the competitive landscape section of the report for the year 2015 in terms of value (%)

Hematological Malignancies Market: Segmentation

The hematological malignancies market has been segmented as Disease condition type, therapy type, distribution channel and geography. Based on disease condition, the market has been segmented into leukemia, lymphoma and myeloma. Likewise, on basis of therapy the market has been categorized into chemotherapy, immunotherapy and targeted therapy. Hospital pharmacies, medical stores and e-commerce platform are included into the market by distribution channel.

Geographically, the hematological malignancies market has been categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Moreover, analysis for the major countries comprising U.S. Canada, Germany, U.K., France, Italy, Spain, Japan, China, Brazil, Mexico, South Africa and Saudi Arabia have also been provided in the report. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the hematological malignancies market in various regions has been provided in this section.

This report also includes various ups and downs about particular country or geography that has impacted the overall market globally. The report provides a detailed outline/blueprint of the hematological malignancies market globally that will assist new companies in establishing their presence and market players in expanding their market share in the market.

Browse Complete Report with TOC at: http://www.transparencymarketresearch.com/hematological-malignancies-market.html

Companies mentioned in the report

The report concludes with the company profile section which includes company overview, financial overview, SWOT analysis, product portfolio, business strategies and recent developments for market players. The major players that are profiled in the report include AbbVie, Inc., Bristol-Myers Squibb, Celgene Corporation, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, and Novartis AG.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Scleroderma Diagnostics and Therapeutics Market Foreseen to Grow Exponentially by 2024

Global Scleroderma Diagnostics and Therapeutics Market: Snapshot

The scleroderma therapeutics and diagnostics market exhibits high potential due to untapped needs and is set to grow rapidly in the near future due to the increasing focus globally on treatment of orphan diseases. The lack of approved drugs in the market makes it a highly opportune condition for players to convert their innovative drug ideas into successful treatment methods for this rare chronic inflammatory disease.

Get Sample Copy of this Report at: http://bit.ly/2m69jBN

According to Transparency Market Research, the global scleroderma diagnostics and therapeutics market was valued at US$1,633.5 mn in 2015 and is projected to expand at a CAGR of 9.7% from 2016 to 2024 to reach US$3,663.7 mn by 2024.

Physician and Patient Preference to make Immunosuppressive Agents Leading Drug Category

Presently, there is no approved drug for treatment of this orphan disease. Although drugs to manage symptomatic relief are available in the scleroderma therapeutics market, the treatment of scleroderma is challenging for a physician, since no two patients are alike in the progress of their disease. Thus, a host of different drugs are prescribed to every patient, depending on the extent, severity and nature of their symptoms.

It has been observed that patient consumption patterns in the global scleroderma diagnostics and therapeutics market are inclined towards immunosuppressive agents, which have shown to provide relief against several symptoms in both systemic and localized scleroderma cases. Moreover, of the very few treatments identified to efficaciously modify the course of scleroderma, physicians often recommend immunosuppressive agents to manage the most common symptoms of the disease. The segment, as a result, accounts for the dominant share in the global market.

Prostacyclin analogues have been found to have a potent effect in treating systemic scleroderma patients who suffer from pulmonary arterial hypertension. However, these drugs are expensive and thus, even though a smaller sub-set of patients is administered with these agents, their market value is high. This segment grabbed over 8.0% share of the global scleroderma therapeutics market in 2015, and is anticipated to slightly decline by 2024 owing to availability of cheaper alternatives within this segment.

Developed Regions to Continue to Command Dominance

Owing to better diagnostic and treatment rates, in part due to proactive awareness-raising initiatives by various foundations, have aided North America and Europe gain the predominant share in the global scleroderma diagnostics and therapeutics market. North America accounted for a share of nearly 34.0% while Europe held nearly 30% of the global scleroderma therapeutics market in 2015. This is attributed to presence of renowned pharmaceutical companies, research organizations, and institutes in the regions, which are focused on finding a standard treatment for the condition.

The North America and Europe markets for scleroderma diagnostics and therapeutics are expected to retain their dominance in the global scleroderma diagnostics and therapeutics market throughout the forecast period, exhibiting CAGRs of 11.2% and 10.9%, respectively, over the period between 2016 and 2024. The ongoing cutting-edge research pertaining to scleroderma will aid the growth of a niche scleroderma diagnostics and therapeutics market in these regions.

Asia Pacific represents some of the world’s key emerging economies, which have the potential to adopt quickly to new therapies, provided they are available at reasonable costs. Due to the price-sensitive nature of the market, as well as availability of cheaper generics and reasonable clinical diagnostic rates compared to North America and Europe, the market for Asia Pacific gained the third position in terms of market share in 2015. The Asia Pacific market will also retain its position in the global market over the forecast period, with factors such as large population and high unmet needs working in favor of market expansion in the region.

Browse Complete Report with TOC at: http://www.transparencymarketresearch.com/scleroderma-diagnostics-therapeutics.html

Actelion Pharmaceuticals, Inc., Boehringer Ingelheim, Bayer AG, Cytori Therapeutics, Inc., Corbus Pharmaceutical Holdings Inc, Cumberland Pharmaceuticals, Inc., Gilead Sciences, Inc., Pfizer, Inc., and Sanofi are some of the key players operating in the global scleroderma diagnostics and therapeutics market.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Pulmonary Drugs Market Forecast to 2024 with Share & Growth Projections in Key Product Segments

Global Pulmonary Drugs Market: Overview

The global pulmonary drugs market has been exceptionally crucial to the overall healthcare industry over the past few years.  According to the research report, the global pulmonary drugs market was worth US$ 48,039.7 mn in 2015 and is likely to reach a valuation of US$ 28,082.1 mn in 2024 as the market will decline at a CAGR of -6.3% during the forecast period of 2016 and 2024. Despite the negative growth rate, the market will find several growth opportunities as the number of chronic respiratory disorders remain on the rise and are fast becoming the cause of death amongst the elderly population.

Get Sample Copy of this Report at: http://bit.ly/2myXaSW

Launch of Effective Drugs Offers New Ray of Hope to Global Market

The Forum of International Respiratory Societies (FIRS) states that chronic obstructive pulmonary disease (COPD) impacts more than 200 million lives and has thus become the fourth leading cause of death across the world. On the other hand, asthma affects around 235 million individuals across the globe. These alarming statistics are expected to boost the market growth despite the declining CAGR in the coming years. Pulmonary drugs are also being used for treating conditions such as allergic rhinitis, pulmonary arterial hypertension (PAH), respiration-related disorders, and cystic fibrosis. The launch of several innovative and effective drugs in the global pulmonary drugs market is also expected to have a positive influence on the growth of the global market in the coming years.

Combination Drugs Remain Favorite amongst Medical Professionals

On the basis of drug classes the global pulmonary drugs market is segmented into inhaled corticosteroids (ICS), long-acting beta2-agonists (LABA), antihistamines, vasodilators, short-acting beta2-agonists (SABA), anticholinergics, combination drugs, and others such as monoclonal antibodies, enzymes, antibiotics, antileukotrienes, etc. Out of these, the combination drugs and inhaled corticosteroids (ICS) held a share of 27.4% and 16.7% respectively in the global market in 2015 in terms of revenue. The demand for combination drugs is estimated to remain high as they are considered to be safer than the others. Furthermore, the introduction of triple combination drugs is also projected to fuel the rise of the global pulmonary drugs market during the forecast period.

Emergence of Middle-income Groups Catapults Demand of Pulmonary Drugs in Asia Pacific

In terms of geography, the global pulmonary drugs market is segmented into Latin America, the Middle East and Africa, Europe, North America, and Asia Pacific. According to analysts, North America held a share of 41.8% in the global market as of 2015. Europe was observed to follow the region’s lead with a significant share of 32.4% in the overall market. The rise of pulmonary drugs market in both these regions is attributable to the well-established health care infrastructure along with an incredible awareness about the treatment options for of pulmonary diseases.

However, analysts anticipate that market in Europe and North America are likely to witness a retarded pace of growth due to patent cliffs in the offing. The U.S. has been making significant contributions to the overall pulmonary drugs market in North America, while Germany remains the steady leader in Europe. The report suggests that Asia Pacific will offer several lucrative opportunities to the global market with the rise of low and middle-income groups and the introduction of several generic pulmonary drugs.

Browse Complete Report with TOC at: http://www.transparencymarketresearch.com/pulmonary-drugs-market.html

Some of the key players operating in the global pulmonary drugs market are Sunovion Pharmaceuticals Inc., AstraZeneca plc, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc, Boehringer Ingelheim GmbH, and Actelion Pharmaceuticals, Inc.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Clostridium Vaccine Market: Global Outlook and Competitive Dynamics 2024

Global Clostridium Vaccine (Animal Health) Market: Scope of the Report

This report on the clostridium vaccine (animal health) market studies the current as well as future prospects of the market globally. Health concern related to life threatening diseases are the major concerns in the developed and developing nations.

Request For Sample Report @ http://bit.ly/2moocQ6

This research report provides a detailed analysis of the clostridium vaccine (animal health) market and helps understand the various driving factors for the growth of the market. The market overview section analyzes market dynamics and trends such as drivers, restraints and opportunities that influence the current nature and future status of the market. Porter’s five forces analysis has been covered in terms of bargaining power of buyers and suppliers, threat of new entrants and substitutes, and competitive rivalry in the global clostridium vaccine (animal health) market. Market dynamics factors such as market attractiveness analysis have also been explained in order to deliver a thorough analysis of the overall competitive scenario of the global clostridium vaccine (animal health) market.

Global Clostridium Vaccine (Animal Health) Market: Segmentation

The clostridium vaccine (animal health) market has been segmented by animal species, by distribution channel and by region. The animal species segment has been sub-segmented into bovine, ovine, caprine, swine, poultry and others. The distribution channel segment has been sub-segments into veterinary clinic, veterinary hospital, veterinary research institute and retail pharmacy.

The executive summary provides detailed insights about the report and the market in general. This elaborate executive summary provides a glimpse into the present scenario of the global clostridium vaccine (animal health) market, which includes a market snapshot that provides overall information of various segments and sub-segments. The executive summary also provides overall information and data analysis of the global clostridium vaccine (animal health) market with respect to market segments based on animal species, distribution channel as well as geographic regions. The market for clostridium vaccine (animal health) has been extensively analyzed based on their usefulness, effectiveness, sales revenue and geographic presence. The market size and forecast in terms of US$ Mn for each animal species and distribution channel has been provided for the period from 2016 to 2024. This report on the clostridium vaccine (animal health) market also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2016 to 2024, considering 2015 as the base year.

Global Clostridium Vaccine (Animal Health) Market: Geographical and Competitive Dynamics

Geographically, the clostridium vaccine (animal health) market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The market size and forecast for each of these regions have been provided for the period from 2016 to 2024, along with CAGR (%) for the forecast period from 2016 to 2024. The research study also incorporates the competitive scenario in these regions.

Browse Complete Report with TOC at: http://www.transparencymarketresearch.com/clostridium-vaccine-market.html

A list of recommendations has been provided for new entrants as well as existing players to help establish a strong presence in the market and increase market share. The report also profiles major players in the clostridium vaccine (animal health) market based on various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Major players profiled in this report include Zoetis, Inc., Merck Animal Health, Sanofi-Aventis (Merial Animal Health), Boehringer Ingelheim, Eli Lilly and Company (Elanco Animal Healthcare), Vibrac Corporation, Bimeda, Inc., Ceva Sante Animale and Bayer AG.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Drugs of Abuse Testing Market - Strategic Assessment and Forecast Till 2024

Global Drugs of Abuse Testing Market: Scope and Methodology

This report on the global drugs of abuse testing market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.

Request For Sample Report at: http://bit.ly/2mFfVDO

The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2015 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global drugs of abuse testing market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

 A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global drugs of abuse testing market.

Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. Market size estimations involved in-depth study of product and product features of different types. Additionally, market related factors such as increasing preference for technologically advanced services, product innovation, and increasing demand for drug abuse testing in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Drugs of Abuse Testing Market: Segmentation

Based on product type, the global drugs of abuse testing market has been segmented three major sub segments namely, analyzers, rapid testing devices and consumables. The analyzers product type segment is further sub – segmented into immunoassay analyzers, chromatographic devices and breath analyzers. The rapid testing devices product type segment is further sub segmented into urine testing devices and oral fluid testing devices. The consumables product type segment is further sub – segmented into fluid collection devices and others. The market has been further studied from the point of view of sample type.

Based on sample type, the market has been segmented into saliva, breath, urine, blood, hair & sweat. On the basis of testing type, the market has been segmented into pain management testing, criminal justice testing and work place screening. Based on the end users the market is categorized into hospitals, diagnostics laboratories, on-the-spot testing and forensic laboratories.

Drugs of Abuse Testing Market: Geographical Outlook

Geographically, the global drugs – of – abuse testing market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries from each region. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, Russia, China, Japan, India, Australia & New Zealand, GCC Countries, South Africa, Brazil, and Mexico.

Browse Complete Report with TOC at: http://www.transparencymarketresearch.com/drugs-abuse-testing-market.html

Key Players Mentioned in the Report are:

The report also profiles major players in the drugs of abuse testing market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Alere Inc., Laboratory Corporation of America Holdings, Roche Diagnostics, Thermo Fisher Scientific Inc., Drägerwerk AG & Co. KGaA, Siemens Healthcare, Express Diagnostics International Inc. and Shimadzu Corporation.

Auto Injectors Market to Witness a Pronounce Growth by 2020

Auto-injectors are hypodermic syringes used to administer a single dose of a drug (typically any life saving drug). These are easy to use and are intended either for self-administration or by untrained personnel. The commercially available auto-injectors are majorly used for the management of anaphylaxis, multiple sclerosis and rheumatoid arthritis. High prevalence of anaphylaxis and food allergies is the major factor propelling the growth of the global auto-injectors market. According to the European Academy of Allergy and Clinical Immunology (EAACI), there has been a seven-fold increase in anaphylaxis related hospital admissions in Europe from 2003 to 2013. Similarly, the Australasian Society of Clinical Immunology and Allergy (ASCIA) stated that the number of anaphylaxis associated hospital admissions increased five times from 2004 to 2014 in New Zealand and Australia. Rising prevalence of anaphylaxis and food allergies is increasing the demand for epinephrine auto-injectors used for anaphylaxis management. Moreover, Healthline Networks, a provider of health information and technology solutions for advertisers, publishers, employers, and health plans and healthcare providers, stated that 2.5 million people were suffering from multiple sclerosis in 2013 worldwide. High prevalence of multiple sclerosis and rheumatoid arthritis is increasing the demand for novel treatment options among the patients, which in turn drives demand for auto-injectors globally.

Get PDF Containing Upcoming Trends of Auto Injectors Market at: http://bit.ly/2lMAte3

Based on product types, the global auto-injectors market has been categorized into prefilled auto-injectors and fillable auto-injectors. Prefilled auto-injectors dominate the auto-injectors market due to their offered ease-of-use and rising patient awareness. Based on Therapeutic Applications, the global auto-injectors market has been segmented into anaphylaxis, multiple sclerosis, rheumatoid arthritis and others. The anaphylaxis segment was the leading and fastest growing market majorly due to high prevalence of the disease, rising awareness about epinephrine auto-injectors and advantages of its use for anaphylaxis management during emergency situations. Based on the manufacturing design, the auto-injectors market has been segmented into standardized auto-injectors and customized auto-injectors. Standardized auto-injectors dominated the market in 2013, as these are the oldest and most preferred auto-injectors with an established record of effective results. However, customized auto-injectors is estimated to be the fastest growing segment, as these offer customization of the dosage of the drug according to age, sex and need of the patient.

Geographically, the global auto-injectors market has been segmented into four major regions: North America, Europe, Asia Pacific, and Rest of the World (RoW). North America dominated the global auto-injectors market in 2013 due to high prevalence of anaphylaxis, favorable government reimbursement policies and economic stability to purchase expensive auto-injectors in the region. On the other hand, Asia Pacific is estimated to be the most promising market for auto-injectors during the forecast period due to rising prevalence of anaphylaxis and multiple sclerosis in New Zealand and Australia coupled with the government reimbursement options in New Zealand, and rising awareness about novel treatment methods available in the market.

The auto-injectors market is consolidated and dominated by a few market players. Mylan, Inc. and Sanofi led the standardized auto-injectors segment due to higher demand for EpiPen and Auvi-Q auto-injectors, respectively. However, the SHL Group dominated the customized auto-injectors segment, with a wide product offering of prefilled customized auto-injectors. The  other major companies operating in the auto-injectors market include Antares Pharma, Inc., Becton, Dickinson and Company, Biogen Idec, Inc., Novartis International AG, Pfizer, Inc., Unilife Corporation and Ypsomed Holdings AG. The auto-injectors market is innovation driven, therefore market players are constantly engaged in research and development activities in order to develop new and effective auto-injectors against various diseases.

Read Current Market Status of Auto-Injectors at: http://www.transparencymarketresearch.com/global-auto-injectors-market.html

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Craniomaxillofacial Implants Market Estimated to Flourish by 2022

With the emergence of resorbable implants, craniomaxillofacial implants are undergoing rapid technological advancement in order to establish an effective treatment platform for facial reconstruction and augmentation. Factors such as growing geriatric population, increasing demand for customized craniomaxillofacial implants, and rising number of road accidents are driving the growth of the global craniomaxillofacial implants market. Furthermore, increasing number of national craniomaxillofacial surgery centers globally that is playing a crucial role in augmenting public awareness about craniomaxillofacial implants and surgery, is another key factor anticipated to support the growth of the craniomaxillofacial implants market. However high cost of the craniomaxillofacial surgery, and lack of appropriate health insurance schemes in developing nations is anticipated to pull back the growth of craniomaxillofacial implants market.

Get Sample Report for the Upcoming Market Trends of Craniomaxillofacial Implants at: http://bit.ly/2l2gfjj

Based on location, the global craniomaxillofacial implants market has been segmented into internal and external fixators. The internal fixator segment accounted for the largest share of the craniomaxillofacial implants market in terms of revenue in 2013. Lesser infection rates, lower incidence of improper healing and stable nature of internal fixators are the major factors attributed to the leading position of the segment. The internal fixator segment is also expected to grow at the highest CAGR during the forecast period due to improvements in the metallurgical formulation of internal fixators, which have in turn increased their corrosion resistance.

The composition segment in the craniomaxillofacial implants market has been categorized into calcium ceramics, metals and alloys, polymers, and biologic materials. Metals and alloys was witnessed as the largest segment in terms of revenue in 2013. The dominance of metals and alloys was majorly witnessed due to improved strength to weight ratio, and better biocompatibility and osseointegration property of metallic craniomaxillofacial implants. However, the biologic material segment is expected to foresee fastest growth rate during the forecast period from 2014 to 2022 due to flexible and resorbable nature of the material, which readily takes any anatomical shape as per the requirement. Furthermore, craniomaxillofacial implants made from biologic material are non-toxic in nature with no inflammatory response, hence accelerating the growth of the market segment during the forecast period.

For the research study, the craniomaxillofacial implants market on the basis of implant nature has been segmented into non-resorbable and resorbable fixators. The non-resorbable fixator segment accounted for the largest share in 2013 due to wide commercial availability and compatibility with the facial tissues. On the other hand, resorbable fixator segment is estimated to witness fastest growth rate during the forecast period. The resorbable fixator gets reabsorbed in the tissue and hence, eliminates the need for repetitive surgical interventions, thereby boosting the growth of this fixator type.

Based on various product types, the craniomaxillofacial implants market has been segmented into plate and screw fixator systems, bone graft substitutes, distraction systems, and temporomandibular joint (TMJ) replacement devices. Plate and screw fixator system held the largest share of the global craniomaxillofacial implants market in 2013. Plate and screw fixators system provide minimum damage to bones and tissues, hence is considered as the most reliable method for the internal fixation of facial and cranial bones. On the other hand, distraction systems are anticipated to expand at the highest CAGR during the forecast period due to increasing jaw deformities resulting from road accidents and genetic problems. The market for distraction systems would show swift growth as these devices result in superior jaw reconstruction which are unavailable with other standard techniques.

Geographically, North America accounted for the largest share of the global craniomaxillofacial implants market in 2013. Factors attributed to the dominant position of North America in craniomaxillofacial implants market were high prevalence of facial injuries and with acceptance of technologically advanced craniomaxillofacial implants. According to the American Association for the Surgery of Trauma, craniomaxillofacial injuries account for over 150,000 deaths every year in the U.S. alone. However, Asia Pacific is anticipated to witness the highest growth during the forecast period. Fastest growth rate in this region is anticipated to emerge due to high prevalence of hereditary facial abnormalities, presence of large base of geriatric population, and improving healthcare infrastructure. According to the latest report published by the National Crime Records Bureau (NCRB), with over 130,000 deaths per year, India has currently has the worst road accident rate in Asia Pacific. Hence, rising rate of road accidents per year in Asian countries is also projected to increase the demand of craniomaxillofacial implants.

Read the Present Market Status of Craniomaxillofacial Implants at: http://www.transparencymarketresearch.com/craniomaxillofacial-implants-market.html

The global craniomaxillofacial implants market is fragmented due to the presence of numerous established as well as emerging players. The prominent companies operating in the craniomaxillofacial implants market includes DePuy Synthes, Stryker Corporation, Biomet, Inc., KLS Martin LP, OsteoMed, Anatomics Pty. Ltd., BIOPORE Surgical Implants, Matrix Surgical USA, Medical Vision Australia Holdings, Poriferous, LLC, General Implants GmbH, Osteotec Ltd., Rebstock Instruments GmbH, B. Braun Melsungen AG, Medartis AG, Medtronic, Inc. and others.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Dental Implants Market Scope and Trends Report 2016 - 2024

Global Dental Implants Market: Snapshot

The global dental implants market is currently being augmented by the increasing number of patients coming forward for treatment of dental caries. A growing number of people – especially from the geriatric demographic – are becoming susceptible to dental problems, therefore increasing the demand for dental implants. The global dental implants market is also being driven by factors such as the growing disposable income of patients from emerging economies and the latest advancements in CAD/CAM tech that is replacing conventional methods. Current factors restraining the global dental implants market include the very high costs of dental implants, especially for patients from emerging economies, followed by the overall lack of reimbursement policies that cover dental work in several countries.

Get PDF Containing the Future Market Analysis of Dental Implants at: http://bit.ly/2lfajyN

The global dental implants market is expected to progress at a CAGR of 7.9% within a forecast period from 2016 to 2024 in terms of revenue. This revenue is expected to reach US$8.18 bn by the end of 2024, after it will reach US$4.46 bn at the end of 2016. In terms of volume, the global dental implants market is expected to expand at a CAGR of 7.9% within the above forecast period.

Global Players Try Their Hand at Localized APAC Dental Implants Market

With Europe leading the global dental implants market currently in terms of overall demand, a greater proportion of key players reside here. This region is also favorable to larger players in terms of popularity and government support, thereby allowing them to accelerate their research and development efforts. Europe is expected to retain its lead in the global dental implants market for 2016, followed closely by North America. On the other hand, globally prominent players are looking towards Asia Pacific for a better revenue stream. Countries from the Asia Pacific region are showing a very high growth in demand for medical facilities, including dental. This is creating a high amount of interest among international names who are trying to expand their business borders.

However, the global players need to work around the massive localized markets present in countries such as India and China. The dental implant market in Asia Pacific, although very large, is dominated by regional entities. This could change over the coming years, as the growing disposable incomes and increasing scope of availing insurance coverage is allowing patients in Asia Pacific to demand for premium quality dental implant products and treatments. This is where global players in the global dental implants market are at an advantage; a lot of the key players possess tools and technologies that are far superior to the conventional methods being used in emerging economies, allowing them to gain a wide level of popularity among these nations.

Titanium Dental Implants Soar in Popularity

In terms of the types of dental implants, the two key segments in the global dental implants market at the moment are titanium implants and zirconium implants. Titanium implants are expected to become the leading segment in the market for 2016 in terms of revenue generation. They are also expected to be the leading segment in the global dental implants market for quite a while. The commonly used forms of titanium alloys in the global dental implants market are extremely tough and resistant to wear and tear and corrosion. At the same time, they are light in weight and can withstand high temperatures. This makes titanium alloys the prime choice for a large number of dental implants. Titanium dental implants are also leading the global dental implants market in terms of growth rate, between 2016 and 2024.

Read the Present Market Status of Dental Implants at: http://www.transparencymarketresearch.com/dental-implants-market.html

The key players currently operating in the dental implants market from a global standpoint, include Danaher Corporation, Dentsply Sirona, Institut Straumann AG, and Zimmer Biomet Holdings, 3M Health Care, and CAMLOG Biotechnologies AG.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Video Telemedicine Market Report Forecasts Strong Growth by 2020

Video communication has been the topic of fascination since the era of the cold war between the United States and the Soviet Russia. Earlier even a small glimpse of human form was considered an achievement. Today, modern technology has advanced to such an extent that even HD video is considered as primitive. This has been possible with the implementation of broadband networks all across the United States and other western countries that have enabled the west to rely on an infrastructure as a fundamental layer for the advancement of video conferencing solutions. The progress in video conferencing technology can be attributed to the three facets that support the industry, namely: device manufacturers, network solution providers and system integrators. The cumulative progress of these industry segments have lead to the overall growth of the video conferencing market, and thereby the video telemedicine applications. Telemedicine during the 1980’s relied heavily on the audio conferencing technology; video conferencing was implemented but with little success as the quality of the video transferred was not great on a dial up connection network. With the integration of fiber optic broadband system and high quality video sensors and webcams, video telemedicine has been touted by many as a revolution in modern medicine enabling face to face visit. Video telemedicine is therefore expected to replace traditional medicine in most aspects, in the near future. With technology advancing at a high pace, this possibility shall soon be a reality.

Get Sample Report for the Upcoming Market Trends of Video Telemedicine at: http://bit.ly/2lf1Rzz

The video telemedicine market is primarily categorized into communication technology and applications. The application segment includes cardiology, neurology, dermatology, orthopedics, oncology, radiology, gynecology, pathology, and dentistry. Gynecology is the segment leader in terms of market revenue among the application areas of video telemedicine. Increasing awareness among women regarding female health risks and rising favor of privacy enabled doctor consultations have lead to the growth of video consultations in gynecology segment. However, neurology segment is witnessing the fastest growth owing to rising number of psychiatric consultation cases. Besides, a range of neurological disorders and conditions such as stroke, Alzheimer’s and Parkinson’s have ensured long term chronic care patient returns that result in increased video consultations. Dentistry, dermatology, oncology and radiology segments however will undergo reserved growth during the forecast period. The application areas such as pathology and cardiology are expected to demonstrate growth potential in the future beyond the forecast period although their present growth rate is not significant. This may be attributed to the increasing prevalence of cardiology diseases and rising concerns regarding contagious infections.

Among the various communication technologies used in video telemedicine, ADSL (Asymmetric Digital Subscriber Line) leads the present video telemedicine market in 2013. On the other hand, 4G (LTE, Wimax, Others) is expected to exhibit the highest growth rate for the forecast period. This can be attributed to the widely present fixed line communication networks such as ADSL and ISDN that are available globally. 4G technologies on the other hand are presently restricted to the western countries where it observes great support and growth and is yet to gain interest in the emerging markets of the Asia Pacific region. 3G technologies come close to being the second most growing technology in video telemedicine. Satellite communication and broadband ISDN (Integrated Services Digital Network) are communication technologies that have an attractive growth potential; however they consist of a smaller fraction of the overall global video telemedicine market.

Geographically, North America was the largest video telemedicine market in terms of revenue for the year 2013 followed by the Europe. The fastest growth is also attributed to North America due to the highly developed and penetrated video telemedicine market in the U.S. Telemedicine itself has roots within the United States and shall continue to directly encourage growth within the video telemedicine solution with the advancement of technology and the rising cost of healthcare in the country. The Asia Pacific region exhibits second fastest growth rate during the forecast period. Rapidly growing population and increasing government initiatives in emerging countries such as China and India are some of the primary reasons why this region boasts of a high growth rate. In addition, the existence of a large number of device manufacturing companies making cheaper equipment and increasing penetration of network providers will ensure steady market penetration and growth for the future.

Read the Present Market Status of Video Telemedicine at: http://www.transparencymarketresearch.com/v-telemedicine-market.html

The video telemedicine market is observed to comprise mainly of device manufacturers, system integrators and network solution providers. Few players present themselves as the largest players in the global video telemedicine market. Among device manufacturers, the largest players are: Logitech International S.A and AMD global Telemedicine. Among network service providers Cisco Sytems Inc. was the largest player and among system integrators Polycom Inc. was the largest player. Overall, in the global video telemedicine market, Cisco Systems, Inc. have the largest global presence, offering a wide range of video telemedicine solutions and services worldwide. Their market presence in emerging markets and expertise in providing software solutions paved the way to their stronghold in the industry. Other companies include Siemens Healthcare, Sony Corporation, GlobalMed Inc., VSee lab Inc., Vidyo Inc., Vermont Tel, LifeSize Communication Inc., Permier Global Services Inc., Huawei Technologies Co Ltd and ZTE Corporation.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Osteoporosis Drugs Market Report Forecasts Impressive Growth by 2020

Osteoporosis is a chronic disease in which the bone density and bone mass is reduced to such an extent that the bones and cartilages become more prone to cracks and fractures. In osteoporosis, the microstructure of bones and amount and number of various proteins is depleted, that leads to not only rise in brittleness and porosity of bones but also failure of bones to regenerate. This condition leads to chronic pain and illness, which could be fatal. Osteoporosis drugs market is semi-consolidated market and the demand for various drugs (inclusive of generic and branded) is increasing at a slow pace, due to steady growth in the prevalence of the disease across the globe. This report is focused towards identifying the current scenario as well as the future market potential for osteoporosis drugs globally. The global osteoporosis drugs market is segmented on the basis of drugs classes available for the treatment of osteoporosis, such as, bisphosphonates, RANK ligand inhibitors (denosumab), calcitonin, parathyroid hormone therapy (PTH), selective estrogen receptor inhibitors (SERMs) and others (estrogen therapy and calcium and vitamin D).

Get PDF Containing the Future Market Analysis of Osteoporosis Drugs at: http://bit.ly/2ml429N

Bisphosphonates is identified as the largest segment, with a share of 48.2% of the total osteoporosis drugs market, as of 2013. Whereas, pipeline drugs is identified as the fastest growing segment growing at a CAGR of 125.2%, during the study period from 2014 to 2020. Rising population of osteoporosis patients across the globe is identified as the major driver of this market, followed by introduction of new drug classes. According to International Osteoporosis Foundation (IOF), every year, osteoporosis causes more than 9 million fractures and bone cracks across the globe. Further, it also stated that, around 200 million women throughout the world are being affected by osteoporosis every year. Thus, increasing prevalence of the disease is considered as an important growth propeller of the market. In addition, introduction of new drug classes to overcome threat of generics and chronic side effects caused by established drugs (brands) is another factor accentuating the growth of osteoporosis drugs market. Recently, new drug classes, such as, parathyroid hormone therapy (PTH) (2008) and denosumab (2010) have been introduced in the market. Due to minimal side effects of the drugs that belong to these classes, the demand and focus of treatment has been shifted towards these treatments. In addition, pipeline products such as, Odanacatib, Romosozumab and BA058-SC are estimated to propel the growth of the market after their regulatory approvals. This growth is likely to observe due to the distinct advantages of these drugs over existing drugs and formulations. The forecast for these products is estimated considering their expected approval and commercialization years.

Geographically, the osteoporosis drugs market is segmented as North America, Europe, Asia-Pacific and Rest of the World (RoW). Presently, the North American region is the largest market in the world, owing to the presence of large number of osteoporosis patients, world-class medical infrastructure, rising awareness about the disease and its treatment and proper utilization of technologically sound devices for diagnosis purpose. However, Asia-Pacific region is considered as the most promising market during the forecast period from 2014 to 2020. The growth is mainly attributed to factors such as steadily increasing incidence rate of osteoporosis, increasing medical expenditure, increased healthcare awareness towards diagnosis and treatment of osteoporosis and dietary habits and lack of nutritious foods.

Read the Present Market Status of Osteoporosis Drugs at: http://www.transparencymarketresearch.com/osteoporosis-drug-market.html

The osteoporosis drugs market is considered as semi-consolidated and is dominated by selective players. More than 63% of the total market share is held by market players such as, Eli Lilly and Company, Pfizer, Inc., Amgen, Inc., Merck & Co., Inc. and Novartis International AG. These players, due to their effective products, dominate the entire market. In addition, other players include F. Hoffmann La Roche Ltd., Actavis plc, Teva Pharmaceutical Industries Ltd. and Novo Nordisk A/S. which contributed to the market with their generic formulations.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Life Science Microscopy Devices Market Opportunities and Forecast till 2020

Microscopy devices have paved the way for innovation in life science through their most potential feature — imaging minute details of any matter. Researchers are able to obtain images of neurons, synapses, cell structure and its processes of high quality using advanced microscopes. Microscopes are also used extensively in academic institutes for primary research. However, the demand for different types of microscopes varies based on the sample type and objective of study. For instance, optical microscopes are used for basic life science research in academic institutes, and private and public research laboratories. Additionally, price of a microscope plays an important role in determining demand, as emerging economies face funding issues. With improving technology, optical microscopes are being increasingly used for advanced life science research. Fluorescence and phase contrast microscopes are realizing their potential extensively in cell biology, pathology and toxicology studies. On the other hand, the use of electron and scanning probe microscopes is rapidly growing with the advancement in the research objectives.

Get PDF Containing the Future Market Analysis of Life Science Microscopy Devices at: http://bit.ly/2ml5d9h

The global life science microscopy devices market has been analyzed based on product type and geography. Three major types of microcopy devices are used in life science research: optical microscope, electron microscope and scanning probe microscope. Optical microscopes are extensively used in life science research because they cost less and address the primary objectives of researchers in academic institutes, and private and public research laboratories. The optical microscopes segment has been sub-segmented based on geography, applications and product type. Cell biology dominated the optical microscopes segment because of their light microscopy features that support cell biology research at minimal cost and effort over other life science applications. Stereo microscopes are the most commonly used optical microscopes in life science research across the world due to their low cost and the ability to generate three-dimensional perspective of the sample under study. However, demand for fluorescence microscopes is increasing rapidly, as staining techniques are being widely used in life science research. On the other hand, phase contrast microscopes are expected to replace fluorescence microscopes in the near future due to their ease of sample preparation and better image capturing features.

Electron microscopes offer high-resolution and magnification power up to 10 million times, which makes them appropriate for the visualization of three-dimensional structures of cells and tissues, determining the spatial arrangement of protein structures and the pathology of disease conditions. The electron microscopes segment has been sub-segmented into transmission electron microscope (TEM) and scanning electron microscope (SEM). The scanning electron microscope segment held the largest share of the global life science electron microscopy devices segment due to low cost and the capability to provide data on taxonomic and systemic parasite studies. However, the demand for transmission electron microscopes, which is an established technique used in cell biology applications, is increasing. Moreover, their use in neuroscience and biomedical engineering is growing rapidly, as researchers gain more interest in the study of brain activity.

The scanning electron microscopes segment has been sub-segmented into atomic force microscope and scanning tunneling microscope. Ease in sample preparation and better imaging is driving the demand for atomic force microscopes. Microscope manufacturers and researchers find these microscopes more useful in neuroscience, biomedical engineering and toxicology studies, as they can be used in vacuum, air, and water. Moreover, electron and scanning probe microscopes find wide applications in neuroscience, as these advanced microscopes offer atomic level imaging of brain sections.

Read the Present Market Status of Life Science Microscopy Devices at: http://www.transparencymarketresearch.com/life-science-microscopy-devices.html

Geographically, North America accounted for the largest share of the global life science microscopy devices market in 2013. However, demand for microscopy devices in Asia Pacific and Latin America is expected to be high during the forecast period due to the growing contract research organization (CRO) market in these regions.

The global life science microscopy devices market is characterized by the presence of few prominent players such as Nikon Corporation, FEI, JEOL Ltd., Leica Microsystems, Hitachi High-technology Corporation, Olympus Corporation, and Carl Zeiss AG.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

U.S. and China Asthma and COPD Drugs Market Is Anticipated To Witness Steady Demand by 2024

U.S. and China Asthma and COPD Drugs Market: Snapshot

The market for asthma and COPD drugs in the U.S. and China is poised to present a steady incremental opportunity in the years to come. A rise in the affected patient pool, an improved diagnosis rate for respiratory diseases, and heightened patient awareness regarding treatment options are identified as the key factors driving this market.

Get PDF Containing the Future Market Analysis of Asthma and COPD Drugs in U.S. and China Region at: http://bit.ly/2lppoPf

The U.S. and China asthma and COPD drugs market is expected to witness moderate growth in the first half of the forecast period, primarily due to the patent expiry of leading drug brands and price erosion in the market. However, by 2020, novel drugs are expected to enter the asthma and COPD drugs market, which is likely to push the market toward a positive future.

The market is slated to expand at a modest CAGR of 4.1% over the course of the forecast period, rising from a valuation of US$13.0 bn in 2015 to US$18.7 bn by 2024.

Recommendations from Global Bodies Drive Preference for Combination Drugs

Based on drug class, in 2015, combination drugs held a prominent share of over 54% in the U.S. and China asthma and COPD drugs market. The segment is slated to witness high growth during the forecast period, which is attributed to the popularity of and preference for combination drugs. The launch of triple combination therapies currently in pipeline by companies such as Chiesi Pharmaceuticals, GSK, and Circassia is also responsible for the growth of this segment.

Both in the U.S. and China, prescription is more inclined toward combination drugs as guidelines by Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommend them as a safer option for the management of asthma and COPD.

An emerging drug class with the potential to create a prominent position in the U.S. and China asthma and COPD drugs market in the coming years is monoclonal antibodies. The launch of new products in this segment is anticipated to bolster its growth during the forecast period.

U.S. Leading Market for Asthma and COPD Drugs; China Most Lucrative

Accounting for a massive 81.4% share in the asthma and COPD drugs market by 2016, the U.S. is the clear leader and will continue its dominance through 2024. This can be primarily attributed to greater awareness among patients and higher prices of asthma and COPD drugs. New product launches, such as FDA-approved Nucala, and a rise in awareness initiatives through apps and educational programs have helped build a strong foundation for treatment in the U.S., making it a profitable country to invest in. Pipeline studies by major players for biologics as well as combination therapies is also a key trend observed over the years. Most prominent companies view the U.S. as a value market, and thus consider it an important part of their new product launch strategy.

In terms of market size, however, the asthma and COPD drugs market in the U.S. is expected to initially decline owing to lower sales triggered by a decrease in revenue from off-patent blockbuster drugs. Nevertheless, new product launches are likely to drive the market from 2021 onward.

Although China accounts for a much smaller share in the U.S. and China asthma and COPD drugs market, it has been identified to be an extremely attractive market, expanding at an impressive CAGR of 10.0% from 2016 to 2024. This is mainly driven by higher unmet medical needs in the country and a rise in the number of asthma patients. The growing incidence of COPD can be attributed to an increase in the number of smokers. A high growth rate, coupled with a low degree of competition in the market compared to the U.S., makes China an attractive investment option for makers of asthma and COPD drugs.

Read the Present Market Status of Asthma and COPD Drugs in U.S. and China Region at: http://www.transparencymarketresearch.com/us-china-asthma-copd-drugs-market.html

Key companies in the U.S. and China asthma and COPD drugs market include GlaxoSmithKline plc, F. Hoffmann-La Roche, AstraZeneca plc, Novartis AG, Boehringer Ingelheim, and Merck and Co., Inc.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Polymerase Chain Reaction Market: Pin-Point Analysis of Industry Trends & Recent Improvement 2020

PCR techniques have paved the way for innovation in life sciences research and molecular diagnostics through its most potential features such as absolute detection and quantification of genetic materials such as DNA and RNA. Researchers are able to quantify and analyze rare alleles and point mutations using advanced PCR systems such as digital PCR. Currently, the market players are engaged in developing PCR systems with enhanced capabilities such as broad menu of tests, higher sensitivity and specificity. Other major advances associated with the PCR include shorter turnaround times (PCR cycling time), higher productivity and automated workflow; thereby ensuring efficient detection and amplification of genetic materials with accurate results. The market is witnessing significant advances in the design of PCR platforms shifting from conventional standard PCR to real time and digital PCR systems to efficiently detect pathogenic microbes such as mycobacterium tuberculosis bacteria and influenza viruses. For instance, introduction of QX200 Droplet Digital PCR System by Bio-Rad provides a broad menu of molecular diagnostic tests and enhanced workflow to enable overall cost reduction and eliminate the need for multiple systems. The global PCR market is valued at USD 6,065 million in 2013 and is expected to reach USD 9,621.0 million with the CAGR of 6.6% during the forecast period of 2014 to 2020.

Obtain the PDF containing Upcoming Market Trends of Polymerase Chain Reaction at: http://bit.ly/2lCGbiS

Although, the use of PCR has been mostly confined to research institutions, pharmaceutical and biotechnology industries, currently, the market has seen an increasing preference of PCR in the commercial diagnostic laboratories and hospitals due to precise diagnoses of life-threatening diseases such as cancer and Ebola. Multi-chain diagnostic laboratories are currently focusing on expanding their operations in less developed areas by acquiring standalone laboratories with minimal infrastructure. Therefore, a strong demand for compact and portable PCR with high reliability and sensitivity is created. All these features along with high affordability are expected to provide impressive growth opportunities for PCR market.

The PCR market is broadly classified on the basis of product segments, end-users and application areas. Among the product segments, reagents and consumables remain the most widely used segment with the largest share in the net sales across various companies, considering the global sales of USD 4,072.2 million in 2013. Among various end-users of PCR, academics and research organization was accounted for the largest market share of overall market in 2013, followed by clinical diagnostic labs and hospitals segment. However, clinical diagnostics segment is likely to grow at an impressive pace during the forecast period of 2014 to 2020. Among the PCR applications area, the life sciences segment is the largest application area covering more than 48% of the total PCR market followed by clinical diagnostics segment with 33% of the market share. The majority market share by the life sciences segment corresponded to its wider acceptance in the cancer research, which is also amongst the oldest segments of PCR application.

Geographically, North America accounted for the largest share of global PCR market in 2013 followed by Europe. These two regions are expected to retain their position throughout the forecast period 2014 to 2020. This is majorly attributed to the presence of technologically sophisticated diagnostic laboratories along with wider acceptance of novel assay technologies. The North American region was among the first to approve and implement the PCR based assays for diagnosis of infectious diseases such as HIV. The Asia Pacific region on the other hand is expected to represent the highest growth rate during the forecast period. This can be attributed to the growing investment in research and development in the region by the Government and private investors. China for example, is at present the world’s second largest investor in research and development according to the World Bank data.

Read the Present Market Status of Polymerase Chain Reaction at: http://www.transparencymarketresearch.com/pcr-technologies.html

The overall PCR market is consolidated and characterized by the presence of few established players accounting for more than 50% of the total market share. Thermo Fisher Scientific, Roche Diagnostics, Abbott Laboratories, Agilent Technologies and Sigma-Aldrich Corporation Beckman Coulter, Bio-Rad, Becton Dickinson and QIAGEN are some of the key players operating in this market.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Bone Morphogenetic Proteins Market Set to Surge Significantly by 2022

Bone morphogenetic proteins (BMP) are naturally occurring proteins found in the human body. Identified in 1965 by Marshall Urist, bone morphogenetic proteins are among the most potent growth factors that induce mesenchymal stem cells to differentiate into osteoblast cells. Twenty different types of BMPs have been discovered to date; only BMP 2, 7 and 9 have osteoinductive property and have been proven to play a significant role in bone formation. However, of these, only BMP-2 and BMP-7 are commercially available. These proteins trigger intracellular signal pathways by binding to the receptor of the mesenchymal stem cells resulting in transformation of stem cells into tissue specific progenitor cells. These cells are involved in the synthesis of musculoskeletal tissue formation, extracellular growth and matrix.

Obtain the PDF containing Upcoming Market Trends of Bone Morphogenetic Proteins at: http://bit.ly/2lMpVxE

The bone morphogenetic proteins market report studies the current scenario as well as future market potential for bone morphogenetic proteins globally. The market overview section of the report comprises qualitative analysis of the overall bone morphogenetic proteins market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s Five Forces analysis and market attractiveness analysis. In addition, various analyses such as event regulatory scenario and value chain analysis have also been provided. Value chain analysis includes the study of major steps involved in the recombinant bone morphogenetic proteins preparation and distribution. Regulatory scenario includes the study of different regulatory norms and procedures that regulate the approval and commercialization of recombinant bone morphogenetic proteins products.

The global bone morphogenetic proteins market has been segmented based on type, application and geography. Based on type, the global BMP market has been categorized into recombinant bone morphogenetic protein-2 (rhBMP-2) and recombinant bone morphogenetic protein-7 (rhBMP-7). Based on application, the bone morphogenetic proteins market has been classified into spinal fusion, trauma, reconstructive and oral maxillofacial surgery. The market for these types and applications has been extensively analyzed on the basis of factors such as product approval date, product demand, sales revenue, geographic presence and product features. The market size and forecast in terms of revenue (USD million) for each of these segments have been provided for the period from 2012 to 2022, considering 2013 and 2014 as the base years. The report also provides the compound annual growth rate (CAGR) for each segment for the forecast period from 2014 to 2022.

Geographically, the BMP market has been classified into four major regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for each region have been provided for the period from 2012 to 2022, in terms of types and applications, along with the CAGR (%) for the forecast period from 2014 to 2022.

Read the Present Market Status of Bone Morphogenetic Proteins at: http://www.transparencymarketresearch.com/bone-morphogenetic-protein-market.html

The bone morphogenetic proteins market report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global bone morphogenetic proteins market in terms of percentage share in 2013 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market shares. The report concludes with the profiles of major players in the global bone morphogenetic proteins market such as Medtronic plc, Stryker Corporation and Cellumed Co. Ltd. The major market players are evaluated on various parameters such as company overview, financial overview, product portfolio, business strategies and recent developments.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Europe Platelet Rich Plasma Market Set to Witness an Uptick by 2022

Platelet rich plasma (PRP) is a blood plasma product that contains elevated level of platelets and growth factors (at least four to ten times) than normal blood concentration. PRP is also called as also called platelet enriched plasma and platelet gel. While mostly derived from patient’s own blood, platelet rich plasma is widely used in the treatment of diseases such as orthopedic diseases, neurological diseases, and other minor injuries that require outpatient surgeries. Rising incidence of diseases such as orthopedic diseases, sports injuries, cardiovascular diseases, obesity, and neurological diseases and introduction of various devices for PRP preparation are the key factors that are likely to drive market growth. In addition, growing awareness about PRP therapy and its advantages, and aging population more prone to injuries and surgeries are the other factors that boost market growth. However, high cost of the devices and therapy and threat of treatment failures are some of the factors restricting the market growth to some extent.

Obtain the PDF containing Upcoming Market Trends of Platelet Rich Plasma in Europe at: http://bit.ly/2mjRgFi

The autologous PRP segment dominated the PRP market in Europe in 2013. The dominance of this market segment was due to increasing demand for allogenic platelet rich plasma products. Thus, the allogenic segment is estimated to grow at the highest growth rate during the forecast period from 2014 to 2022. The growth of this market segment was majorly due to reduced wound healing time and high concentration of growth factors containing platelet rich plasma products. In case of a patient diagnosed with one of the blood disorders (leukemia, hemocytopenia, etc) with less number of platelets in the blood and without any significant clinical action, where allogenic PRP treatment would be recommended.

Orthopedic was the largest application segment in 2013, accounting for 38.3% share of the PRP market in Europe. Large number of orthopedic and sports injuries and rise in geriatric population are the major factors driving the growth of this application segment. PRP products are widely used in cosmetic surgeries to enhance the rate of injury healing, improve facial aesthetics, and facelift treatments. In addition, cost-effectiveness and multiple applications of PRP in cosmetic surgeries are the major factors accelerating the growth of this segment. Therefore, these factors collectively propel the growth of cosmetic surgery application segment and it is estimated to grow at a highest rate during the forecast period from 2014 to 2022.

Geographically, the Europe platelet rich plasma market has been segmented as U.K., Germany, Italy, France, Spain and Rest of Europe. In 2013, U.K. dominated the Europe PRP market primarily due to increasing prevalence of orthopedic and reconstructive procedures and growing number of bariatric surgeries. Thus, PRP therapy is gaining wider acceptability as it provides effective treatment and faster recovery. For instance, tennis elbow affects around 300,000 people in the U.K. every year, where PRP is the most preferred treatment option. Moreover, growing preference for PRP therapy for sports injuries would boost market growth in the U.K.

Read the Present Market Status of Platelet Rich Plasma in Europe at: http://www.transparencymarketresearch.com/europe-platelet-rich-plasma-market.html

The Europe PRP market is highly fragmented with the presence of a large number of small and large multinational players. Companies such as Arthrex, Inc., Biomet, Inc., and EmCyte Corporation dominated the Europe PRP market in 2013. Other minor players present in the Europe PRP market include AdiStem Ltd., Glofinn Oy, Medira Ltd., and Regen Lab SA.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/